초록 열기/닫기 버튼
Purpose: To compare the clinical efficacy of intravitreal ranibizumab and aflibercept in treatment-naïve patients with polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively analyzed the medical records of 82 eyes with treatment-naïve PCV who were treated with ranibizumab or aflibercept and followed for at least six months. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) as measured by optical coherence tomography (OCT), and polyp size in indocyanine green angiography (ICGA) were used for evaluation. The primary endpoint was change at 12 months relative to baseline with respect to BCVA and CFT. Secondary endpoints were anatomical changes in OCT and ICGA findings from baseline. Results: Data from 46 eyes were considered for the primary endpoint. Twenty-five and 21 eyes received ranibizumab and aflibercept, respectively. Statistically significant improvements in BCVA and CFT compared with baseline were noted in both groups. Of 82 eyes assessed for secondary endpoints, 52 and 30 received ranibizumab and aflibercept, respectively. The subretinal fluid , pigment epithelial detachment , and subfoveal thickness decreased significantly throughout the follow-up in each group. Polyp regression was found in 37.5% and 32.4% of the ranibizumab- and aflibercept-treated groups, respectively. However, there was no significant difference in the treatment results between the drugs. Conclusions: In a comparison of the clinical efficacy of intravitreal ranibizumab and that of aflibercept in patients with PCV, the treatment groups showed similar clinical results in terms of functional and anatomical outcomes after 12 months.
